Affimed N.V. (AFMD) got here out with a quarterly lack of $0.08 per share versus the Zacks Consensu
Affimed N.V. (AFMD) got here out with a quarterly lack of $0.08 per share versus the Zacks Consensus Estimate of a lack of $0.12. This compares to lack of $0.19 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of 33.33%. 1 / 4 in the past, it was anticipated that this drug developer would submit a lack of $0.12 per share when it truly produced a lack of $0.18, delivering a shock of -50%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
Affimed N.V.Which belongs to the Zacks Medical – Biomedical and Genetics trade, posted revenues of $12.33 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 94.55%. This compares to year-ago revenues of $2.34 million. The corporate has topped consensus income estimates simply as soon as during the last 4 quarters.
The sustainability of the inventory’s speedy value motion primarily based on the recently-released numbers and future earnings expectations will largely rely on administration’s commentary on the earnings name.
Affimed N.V. Shares have added about 36.1% because the starting of the 12 months versus the S&P 500’s achieve of 9.9%.
What’s Subsequent for Affimed N.V.
Whereas Affimed N.V. Has outperformed the market thus far this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There aren’t any straightforward solutions to this key query, however one dependable measure that may assist traders deal with that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but in addition how these expectations have modified currently.
Empirical analysis exhibits a powerful correlation between near-term inventory actions and traits in earnings estimate revisions. Traders can monitor such revisions by themselves or depend on a tried-and-tested ranking instrument just like the Zacks Rank, which has a powerful monitor document of harnessing the ability of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for Affimed N.V. Was blended. Whereas the magnitude and path of estimate revisions might change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in keeping with the market within the close to future. You’ll be able to see the whole listing of at this time’s Zacks #1 Rank (Sturdy Purchase) shares right here.
Will probably be fascinating to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.07 on $12.66 million in revenues for the approaching quarter and -$0.49 on $28.24 million in revenues for the present fiscal 12 months.
Traders ought to be aware of the truth that the outlook for the trade can have a fabric impression on the efficiency of the inventory as effectively. By way of the Zacks Trade Rank, Medical – Biomedical and Genetics is at present within the backside 25% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
Need the newest suggestions from Zacks Funding Analysis? At the moment, you’ll be able to obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report
Affimed N.V. (AFMD): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.